Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 15, Issue 3, 2000, Pages 347-354

  Bach, Leon A ^a   Dean, Rachael ^a   Youssef, Sherrif ^a   Cooper, Mark E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Advanced glycation; Binding protein; Diabetic nephropathy; Immunohistochemistry; In situ hybridization; Insulin like growth factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; STRUCTURAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; GENE EXPRESSION REGULATION; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033994790     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.3.347     Document Type: Article

References (44)

1. Wardle EN. How does hyperglycaemia predispose to diabetic nephropathy? Q J Med 1996; 89: 943-951
2. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43: 836-841
3. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334
4. Pugliese G, Pricci F, Romeo G et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997; 46: 1881-1887
5. Flyvbjerg A, Landau D, Domene H, Hernandez L, Gronback H, LeRoith D. The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. Metabolism 1995; 44: 67-71
6. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Rev 1992; 8: 229-257
7. Ziyadeh FN, Han DC. Involvement of transforming growth factor-beta and its receptors in the pathogenesis of diabetic nephrology. Kidney Int 1997; 60 [Suppl]: S7-11
8. Flyvbjerg A, Thorlacius-Ussing O, Naeraa R, Ingerslev J, Orskov H. Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomised rats. Diabetologia 1988; 31: 310-314
9. Bach LA, Jerums G. Effect of puberty on initial kidney growth and rise in kidney IGF-I in diabetic rats. Diabetes 1990; 39: 557-562
10. Flyvbjerg A, Frystyk J, Osterby R, Orskov H. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am J Physiol 1992; 262: E956-962
11. Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Orskov H. Octreolide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion Kidnev Int 1992; 41: 805-812
12. Gronbaek H, Vogel I, Osterby R, Lancranjan I, Flyvbjerg A, Orskov H. Effect of octreotide, captopril or insulin on renal changes and UAE in long-term experimental diabetes Kidney Int 1998; 53: 173-180
13. Gronbaek H, Volmers P, Bjorn SF, Osterby R, Orskov H, Flyvbjerg A. Effect of GH/IGF-1 deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats. Am J Physiol 1997; 272: E918-924
14. Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38-61
15. Luo J, Murphy LJ. Differential expression of insulin-like growth factor-I and insulin-like growth factor binding protein-1 in the diabetic rat. Mol Cell Biochem 1991; 103: 41-50
16. Bach LA, Cox AJ, Mendelsohn FAO, Herington AC, Werther GA, Jerums G. Focal induction of IGF-I binding proteins in proximal tubules of diabetic rat kidney. Diabetes 1992; 41: 499-507
17. Ooi GT, Tseng LY-H, Tran MQ, Rechter MM. Insulin rapidly decreases IGFBP-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992; 6: 2219-2228
18. Flyvbjerg A, Kessler U, Dorka B, Funk B, Orskov H, Kiess W. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 1992; 35: 589-593
19. Landau D, Chin E, Bondy C et al. Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes. Endocrinology 1995; 136: 1835-1842
20. Price GJ, Berka JL, Werther GA, Bach LA. Cell-specific regulation of mRNAs for IGF-I and IGF-binding proteins 4 and 5 in streptozotocin-diabetic rat kidney. J Mol Endocrinol 1997; 18: 5-14
21. Price GJ, Berka JL, Edmonson SR, Werther GA, Bach LA. Localization of mRNAs for insulin-like growth factor binding proteins 1 to 6 in rat kidney. Kidney Int 1995; 48: 402-411
22. Le Moine C, Bernard V, Bloch B. Quantitative in situ hybridization using radioactive probes in the study of gene expression in heterocellular systems. In: Choo KHA, ed. Methods in Molecular Biology: In Situ Hybridization Procedures. Humana Press, Totowa, NJ, 1994; 301-311
23. Bach LA, Stevenson IL, Allen TJ, Jerums G, Herington AC. Kidney insulin-like growth factor-I mRNA levels are increased in postpubertal diabetic rats. J Endocrinol 1991; 129: 5-10
24. Catanese VM, Sciavolino PJ, Lango MN. Discordant, organ-specific regulation of insulin-like growth factor-I messenger ribonucleic acid in insulin-deficient diabetes in rats Endocrinology 1993; 132: 496-503
25. Flyvbjerg A, Bornfeldt KE, Marshall SM, Arnqvist HJ, Orskov H. Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes mellitus. Diabetologia 1990; 33: 334-338
26. Weiss O, Anner H, Nephesh I, Alayoff A, Bursztyn M, Raz I. Insulin-like growth factor-I (IGF-I) and IGF-I receptor gene expression in the kidney of the chronically hypoinsulinemic rat and hyperinsulinemic rat. Metabolism 1995; 44: 982-986
27. Fervenza FC, Tsao T, Hoffman AR, Rabkin R. Regional changes in the intrarenal insulin-like growth factor-I axis in diabetes. Kidney Int 1997; 51: 811-818
28. Andersson GL, Skottner A, Jennische E. Immunocytochemical and biochemical localization of insulin-like growth factor I in the kidney of rats before and after uninephrectomy. Acta Endocrinol 1988; 119: 555-560
29. Kobayashi S, Clemmons DR, Venkalachalam MA. Colocalization of insulin-like growth factor-binding protein with insulin-like growth factor I. Am J Physiol 1991; 261: F22-28
30. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague Dawley rat. Diahetologia 1995; 38: 387-394
31. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996; 50: 627-634
32. Soulis T, Cooper ME, Sastra S et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997; 40: 1141-1151
33. Yamauchi A, Takei I, Makita Z et al. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albumin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long Evans Tokushima fatty rats. Diab Res Clin Prac 1997; 34: 127-133
34. Ellis EN, Good BH. Prevention of glomerular basement thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991; 40: 1016-1019
35. Busby WH, Jr., Klapper DG, Clemmons DR. Purification of a 31000-dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions. J Biol Chem 1988; 263: 14203 14210
36. Kirstein M, Aston C, Hintz R, Vlassara II. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90: 439-446
37. Doi T, Viassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1991; 89: 2873-2877
38. Zheng B, Duan C, Clemmons DR. The effect of extracellular matrix proteins on porcine smooth muscle cell insulin-like growth factor (IGF) binding protein-5 synthesis and responsiveness to IGF-I. J Biol Chem 1998; 273: 8994-9000
39. Bader R, Bader E, Grung KE, Markensen-Haen S, Christ H, Bohle A. Structure and function of the kidney in diabetic glomerulosclerosis: Correlations between morphological and functional parameters. Pathol Res Pract 1980; 167: 204-216
40. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int (in press)
41. Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and the receptor for advanced glycated end products co-localise in organs susceptible to diabetic microvascular injury: immunohistochemical studies. Diabetologia 1997; 40: 619-628
42. Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int 1999; 55: 907-916
43. Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes 1998; 47: 414-422
44. Cordonnier DJ, Pinel N, Barro C et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999; 10: 1253-1263